NEW YORK, April 05, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community.Today we are offering reports on NEPT, CUR, NLNK, and OHRP which can be accessed for free by signing up to www.wallstequities.com/registration. Today, WallStEquities.com shifts focus on Biotechnology, which focuses on novel drug development and clinical
Neptune Technologies & Bioressources
Shares in Laval, Canada headquartered Neptune Technologies & Bioressources Inc. saw a decline of 1.41%, ending Wednesday's trading session at $2.80. The stock recorded a trading volume of 288,296 shares. The Company's shares have gained 17.65% in the last month, 17.15% over the last three months, and 182.54% over the past year. The stock is trading 69.03% above its 200-day moving average. Moreover, shares of the Company, which focuses on the research, development, and commercialization of products derived from marine biomasses for the nutraceutical and pharmaceutical industries, have a Relative Strength Index (RSI) of 46.01. Get the full research report on NEPT for free by clicking below at: www.wallstequities.com/registration/?symbol=NEPT
Germantown, Maryland headquartered Neuralstem Inc.'s stock jumped 6.88%, closing the day at $1.71 with a total trading volume of 81,961 shares. The Company's shares have advanced 8.92% in the past month. The stock is trading 1.92% above its 50-day moving average. Additionally, shares of Neuralstem, which focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds, have an RSI of 53.52.
On April 02nd, 2018, Neuralstem reported its financial results for the year ended December 31st, 2017. Operating loss for the full year was $13.3 million, net loss was $15.7 million, R&D expenses were $8.1 million, and G&A expenses were $5.5 million. At December 31st, 2017, cash and investments were $11.7 million. Access the free research report on CUR now by signing up at: www.wallstequities.com/registration/?symbol=CUR
On Wednesday, shares in Ames, Iowa headquartered NewLink Genetics Corp. recorded a trading volume of 650,054 shares. The stock ended the day 3.68% higher at $7.32. The Company's shares are trading below their 50-day moving average by 4.08%. Furthermore, shares of NewLink Genetics, which focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer, have an RSI of 46.98.
On March 21st, 2018, NewLink Genetics announced the appointment of Chad A. Johnson, 39, to its Board of Directors. In connection with this appointment, the Board expanded from seven directors to eight. Are you already registered with Wall St. Equities? Do so now for free, and get the report on NLNK at: www.wallstequities.com/registration/?symbol=NLNK
New York headquartered OHR Pharmaceutical Inc.'s stock dropped slightly by 0.18%, finishing yesterday's session at $0.22 with a total trading volume of 375,661 shares. The stock is trading below their 50-day moving average by 17.87%. Shares of the Company, which focuses on the development of novel therapies for the treatment of ophthalmic diseases, have an RSI of 37.67. Aspiring Member, please take a moment to register below for your free research report on OHRP at: www.wallstequities.com/registration/?symbol=OHRP
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: email@example.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/technical-perspectives-on-biotech-stocks----neptune-technologies--bioressources-neuralstem-newlink-genetics-and-ohr-pharma-300624893.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Fallot's tetralogy is a rare and complex birth defect of the heart. Babies born with this condition ...
Bubonic plague is an infectious disease caused by the bacteria Yersinia pestis present in rodents ...
Steroids are miracle drugs but have to be used with caution. Some steroids are illegal to use, ...View All